Navigation Links
Vela Laboratories Receives the GMP Certificate for Its Analytical and Quality Control Laboratories
Date:4/7/2008

VIENNA, April 7 /PRNewswire/ -- Vela Laboratories announced today that it has received the GMP certificate for its analytical and quality control laboratories. "Good Manufacturing Practice" is a body of internationally accepted regulations set forth by EU and US drug agencies. GMP compliance ensures that pharmaceuticals , active ingredients and medical devices are pro­duced and quality-controlled according to state-of-the-art standards.

"GMP compliance is the gold standard in quality assurance in the life science industry. It is a major achievement for Vela Labs to have reached the GMP certification just 18 months since its formation," said Dr. Markus Fido, founder and CEO of Vela Laboratories. "Now that Vela Laboratories is GMP certified, its analytical services fully qualify to support clinical studies as well as regulatory submissions."

"GMP certification is an important milestone for our analytical services business. Now we will start to consistently expand our analytical methods portfolio that we are offering to the pharmaceutical and biotech industry," said Dr. Andreas Nechansky, founder of Vela Labo­ratories and Chief Operating Officer.

"Having achieved GMP compliance enables Vela to develop its therapeutic anti-cancer anti­bodies in the shortest time possible and with the highest quality," said Dr. Ralf Kircheis, founder of Vela Laboratories and Chief Scientific Officer.

About Vela Laboratories

Vela Laboratories (Vela pharmazeutische Entwicklung und Laboranalytik GmbH) provides a broad portfolio of analytical methods for the preclinical and clinical development including studies in support of regulatory submissions and product release for biopharmaceuticals.

Additionally, Vela Laboratories develops innovative immunotherapeutics for the treatment of cancer, including therapeutic antibodies and multi-epitope vaccines. Vela Laboratories' lead product, a humanized monoclonal antibody against a common tumor antigen, is in clinical development. In addition, Vela Laboratories also has development programs underway that aim at improving the efficacy and tolerability of therapeutic antibodies through targeted changes to the sugar structure of the antibody molecules.

The Company, headquartered in Vienna, Austria, was founded in November 2006. Vela Laboratories is funded by private investors, by grants from Austrian government agencies (AWS and ZIT/LISA) and through revenues generated by its analytical services business.

Contact:

Jakob Koschutnig

Head Marketing & Sales

Vela Laboratories

Brunner Str. 69 / 3

1230 Vienna, Austria

Mobile: +43(0)699-1314-3-123

Fax: +43(0)1-890-597-9-10

E-mail: j.koschutnig@vela-labs.at

Web: http://www.vela-labs.at


'/>"/>
SOURCE Vela Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
2. Stonegate Report About Unigene Laboratories Inc.
3. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
4. White Paper Details Environmental Health & Safety Compliance Strategies for Laboratories
5. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
6. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
7. Clontech Laboratories, Inc. Releases the ProteoTuner(TM) Systems
8. Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement
9. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
10. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
11. Free White Paper Helps Biotech Laboratories Maintain a High Level of Infection Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief ... ), Inc. has been selected for membership in ARCS Alumni Hall of ...
(Date:10/11/2017)... ... ... is a basic first aid supply for any work environment, but most personal eye wash ... if a dangerous substance enters both eyes? It’s one less decision, and likely quicker response ... piece. , “Whether its dirt and debris, or an acid or alkali, getting anything in ...
(Date:10/11/2017)... ... 2017 , ... Proscia Inc ., a data solutions ... “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, Managing ... how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
Breaking Biology Technology:
(Date:8/15/2017)... Va. , Aug. 15 2017   ivWatch LLC , ... of intravenous (IV) therapy, today announced receipt of its ISO 13485 ... developed by the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the ... "This is ...
(Date:6/23/2017)... and ITHACA, N.Y. , ... and Cornell University, a leader in dairy research, today ... bioinformatics designed to help reduce the chances that the ... the onset of this dairy project, Cornell University has ... for Sequencing the Food Supply Chain, a food safety ...
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
Breaking Biology News(10 mins):